Combinations of acetylcholinesterase inhibitors and muscarinic agonists and methods of use thereof

Abstract

A method of treating one or more symptoms associated with underactive bladder in a patient suffering therefrom by administering to the patient a therapeutically effective amount of an acetylcholinesterase inhibitor (AChEI) and an amount of a muscarinic receptor agonist effective to reduce the volume of post void residual in the patient obtained by treatment with the AChEI alone.

What I claim is: 
     
         1 . A composition for treating patient suffering from underactive bladder comprising an acetylcholinesterase inhibitor (AChEI) selected from the group consisting of donepezil, tacrine, edrophonium, physostigamine, neostigamine, pyridostigamine, rivastgmine or pharmaceutically acceptable salts thereof and any combinations thereof and a muscarinic receptor agonist selected from the group consisting of bethanechol, acethylcholine, methacoline, carbachol, muscarine, arecoline, pilocarpine, acceptable salts thereof and any combinations thereof. 
     
     
         2 . The composition of  claim 1 , wherein said AChEI is donepezil or its pharmaceutically acceptable salt thereof. 
     
     
         3 . The composition of  claim 1 , wherein the muscarinic receptor agonist is bethanechol or a pharmaceutically acceptable salt thereof. 
     
     
         4 . The composition of  claim 1 , further comprising a third active ingredient that is an alpha receptor agonist selected from the group consisting of prazosin, terazosin, doxazosin, alfuzosin, tamulosin, or a pharmaceutically acceptable salt thereof and a combination thereof. 
     
     
         5 . The composition of  claim 1 , further comprising an immediate release and a delayed release component. 
     
     
         6 . The composition of  claim 5 , wherein the immediate release component comprises at least one AChEI selected from the group consisting of donepezil, tacrine, edrophonium, physostigamine, neostigamine, pyridostigamine, rivastgmine or a pharmaceutically acceptable salt thereof and the delayed release component comprise a muscarinic receptor agonist selected from the group consisting of bethanechol, acethylcholine, methacoline, carbachol, muscarine, arecoline, pilocarpine, any natural alkaloid and a pharmaceutically acceptable salt thereof 
     
     
         7 . The composition of  claim 6 , wherein said AChEI is donepezil or pharmaceutically acceptable salts thereof. 
     
     
         8 . The composition of  claim 7 , wherein the muscarinic receptor agonist is bethanechol or a pharmaceutically acceptable salt thereof. 
     
     
         9 . A method of treating a patient suffering from underactive bladder comprising administering to said patient a composition comprising an acetylcholinesterase inhibitor (AChEI) selected from the group consisting of donepezil, tacrine, edrophonium, physostigamine, neostigamine, pyridostigamine, rivastgmine or pharmaceutically acceptable salts thereof and any combinations thereof and a muscarinic receptor agonist selected from the group consisting of bethanechol, acethylcholine, methacoline, carbachol, muscarine, arecoline, pilocarpine, acceptable salts thereof and any combinations thereof. 
     
     
         10 . The method of  claim 9 , wherein said AChEI is donepezil or its pharmaceutically acceptable salt thereof. 
     
     
         11 . The method of  claim 8 , wherein the muscarinic receptor agonist is bethanechol or a pharmaceutically acceptable salt thereof.